| Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA962 | | |
| Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) | TA965 | | |
| Ritlecitinib for treating severe alopecia areata in people 12 years and over | TA958 | | |
| Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis | TA959 | | |
| Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) | TA960 | | |
| Desflurane for maintenance of anaesthesia | ES41 | | |
| Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment | HTE17 | | |
| Ovarian cancer: identifying and managing familial and genetic risk | NG241 | | |
| Momelotinib for treating myelofibrosis-related splenomegaly or symptoms | TA957 | | |
| Suspected sepsis: recognition, diagnosis and early management | NG51 | | |
| Neonatal infection: antibiotics for prevention and treatment | NG195 | | |
| Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management | NG240 | | |
| ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment | HTE5 | | |
| Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | TA878 | | |
| Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema | TA953 | | |
| Dupilumab for treating moderate to severe prurigo nodularis | TA955 | | |
| Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over | TA956 | | |
| Lung cancer: diagnosis and management | NG122 | | |
| Vitamin B12 deficiency in over 16s: diagnosis and management | NG239 | | |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA954 | | |
| Digital technologies for delivering multidisciplinary weight-management services: early value assessment | HTE14 | | |
| Digital technologies for managing non-specific low back pain: early value assessment | HTE16 | | |
| Endoscopic sleeve gastroplasty for obesity | IPG783 | | |
| Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations | TA952 | | |
| Tuberculosis | NG33 | | |
| Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over | TA949 | | |
| Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over | TA950 | | |
| Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | | |
| Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments | TA947 | | |
| Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 | | |
| Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) | TA945 | | |
| Caesarean birth | NG192 | | |
| Devices for remote monitoring of Parkinson's disease | DG51 | | |
| COVID-19 rapid guideline: managing the long-term effects of COVID-19 | NG188 | | |
| Skin cancer | QS130 | | |
| Pharyngeal electrical stimulation for neurogenic dysphagia | IPG781 | | |
| Temperature control to improve neurological outcomes after cardiac arrest | IPG782 | | |
| Neonatal infection | QS75 | | |
| Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | | |
| Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | | |
| Sebelipase alfa for treating Wolman disease | HST30 | | |
| Intravascular lithotripsy for calcified arteries in peripheral arterial disease | IPG780 | | |
| Bipolar disorder: assessment and management | CG185 | | |
| Targeted-release budesonide for treating primary IgA nephropathy | TA937 | | |
| Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) | TA940 | | |
| Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) | TA941 | | |
| Empagliflozin for treating chronic kidney disease | TA942 | | |
| Epilepsies in children, young people and adults | QS211 | | |
| Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | | |
| Risdiplam for treating spinal muscular atrophy | TA755 | | |